3919 |
The REDUCE-FMR Trial |
Horst Sievert |
Apr. 27. 19 |
3918 |
Pathophysiological Types and Biomarkers of Acute Myocardial Infarction |
Buxing Chen |
Apr. 27. 19 |
3917 |
The MITRA-FR Trial: Why the Trial Fails? |
Thierry Lefevre |
Apr. 27. 19 |
3916 |
Pharmacotherapy After TAVR: Antiplatelet or Anticoagulation Therapy |
Do-Yoon Kang |
Apr. 27. 19 |
3915 |
Expanding Indication of TAVR: Ongoing Trials and Expectations |
Alan C. Yeung |
Apr. 27. 19 |
3914 |
TAVR in 2019: Appropriate Patient and Device Selection |
Eberhard Grube |
Apr. 27. 19 |
3913 |
TAVR: Long Journey from Concept to Human |
Alain G. Cribier |
Apr. 27. 19 |
3912 |
Clinical Characteristics and Prognosis of AMI Patients in China |
Hongbing Yan |
Apr. 27. 19 |
3911 |
Bifurcation Tip & Tricks/Tansei |
Yutaka Hikichi |
Apr. 27. 19 |
3910 |
Lessons Learned from COBIS Studies |
Young Bin Song |
Apr. 27. 19 |